Overview
Ablynx's NANOBODY® technology platform uses tiny, modular antibodies to unlock new possibilities in drug design. The company was acquired by Sanofi, which now operates the technology platform as part of its drug development capabilities.
In the news
Alumni 3 went on to found or lead
Carlo BouttonDirector Technology & Information Management→Chief Scientific Officer at Biotalys at Biotalys
Khalil El MazouariBioinformatics Manager→Founder & CEO at AbnomX
Dries VandevyvereIT Project Manager→Growth & Partnerships at Eye on Data
Tim Van HauwermeirenSenior Business Development Executive→Chairman of the Board at argenx
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.